[Pharmacokinetic, bacteriological and clinical studies on sulbactam/ampicillin in pediatric field].
Clinical trials were carried out on the use of sulbactam/ampicillin (SBT/ABPC) (combination rate of 1:2) in pediatric infections. Results were as follows: 1. The mean half-lives of SBT and ABPC in the serum following intravenous injection of SBT/ABPC were about 1.05 and 0.90 hours, respectively. 2. The mean urinary excretions of SBT and ABPC in 6 hours after intravenous injection of SBT/ABPC were 71.2% and 62.2%, respectively. 3. SBT/ABPC was administered to 23 pediatric patients with various infections: 17 patients with pneumonia, 3 with tonsillitis, 2 with urinary tract infection and 1 with cervical lymphadenitis. The overall efficacy rate was 95.7%. In particular, 2 urinary tract infections caused by highly beta-lactamase producing Escherichia coli were improved by the treatment with SBT/ABPC. 4. No adverse reactions were observed except 2 cases of mild diarrhea. Abnormal laboratory test values included thrombocytosis in 4 and slight elevation of GOT and GPT in 1, but they were transient.
Nakao
Y
Y
Department of Pediatrics, Anjo Kosei Hospital.
Kimura
H
H
Miura
K
K
Miyajima
Y
Y
Ishikawa
H
H
Hayakawa
F
F
Kuno
K
K
D000367:Age Factors; D000667:Ampicillin / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects / Q000302:isolation & purification; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D005260:Female; D006207:Half-Life; D006801:Humans; D007223:Infant; D007275:Injections, Intravenous; D008297:Male; D010403:Penicillin Resistance; D013407:Sulbactam / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology
D000667:Ampicillin; D013407:Sulbactam